MedPath

Collagenase clostridium histolyticum

Generic Name
Collagenase clostridium histolyticum
Brand Names
Qwo, Santyl, Xiaflex
Drug Type
Biotech
CAS Number
9001-12-1
Unique Ingredient Identifier
9X7O8V25IT
Background

Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers.

On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women. Also known as Qwo, this injection is the first approved injectable treatment for cellulite and was developed by Endo International.

Indication

Collagenase clostridium histolyticum is indicated for the treatment of adults with Dupuytren's contracture with a palpable cord. Additionally, it is used to treat men with Peyronie's disease diagnosed with a penile curvature deformity of at least a 30-degree angle at the beginning of therapy in addition to palpable plaques. Collagenase ointment is used for the tissue debridement of chronic dermal ulcers and severely burned tissues.

The combination collagenase product, also known as Qwo, is used for the treatment of moderate to severe cellulite in the buttocks of adult women.

Associated Conditions
Dupuytren's Contracture of the Hand (Viking's Disease), Peyronie's Disease, Necrotic tissue
Clinical Trials
Related News

MediWound Initiates Phase III Trial of EscharEx for Venous Leg Ulcers

• MediWound has commenced a Phase III clinical trial (VALUE) to evaluate EscharEx for the treatment of venous leg ulcers (VLUs). • The VALUE trial is a randomized, double-blind, placebo-controlled study across 40 sites in the U.S. and Europe, enrolling 216 patients. • EscharEx has shown promise in Phase II trials, demonstrating effective and rapid debridement of chronic wounds, potentially redefining VLU treatment. • An interim analysis of the VALUE trial is expected in mid-2026, with strategic collaborations in place to ensure consistent wound management.

MediWound Initiates Phase II Trial of EscharEx for Venous Leg Ulcer Treatment

• MediWound has commenced a Phase II clinical trial to assess EscharEx for treating venous leg ulcers, with results expected to support a BLA submission. • The trial is a randomized, multicenter study comparing EscharEx to collagenase ointment (Santyl) and placebo across 45 patients in the U.S. and Europe. • Strategic R&D collaborations with Solventum and Mölnlycke Health Care will ensure consistency in the study through the use of advanced wound care products. • EscharEx, a bioactive debridement therapy, has shown promise in earlier trials and is also being developed for diabetic foot ulcers.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy